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Abstract
Edema disease, a naturally occurring disease of swine caused by Shiga toxin-producing Escherichia coli
(STEC), was used as a model for the sequence of events that occur in the pathogenesis of STEC infection. The
mean time from production of levels of Shiga toxin 2e (Stx2e) detectable in the feces (day 1) to the onset of
clinical disease (neurologic disturbances or death) was 5 days (range, 3–9). Bacterial colonization and titers of
Stx2e in the ileum peaked at 4 days after inoculation in pigs without signs of clinical disease and at 6 days after
inoculation in clinically affected pigs. Animals with the greatest risk of progressing to clinical disease tended to
have the highest fecal toxin titers (⩾1 : 4096). Stx2e was detected in the red cell fraction from blood of some
pigs showing clinical signs of edema disease but was not detected in the serum or cerebrospinal fluid.
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Shiga Toxin–Producing Escherichia coli Infection: Temporal and Quantitative
Relationships among Colonization, Toxin Production, and Systemic Disease
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and 2Enteric Diseases and Food Safety Research Unit, National
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Edema disease, a naturally occurring disease of swine caused by Shiga toxin–producing
Escherichia coli (STEC), was used as a model for the sequence of events that occur in the
pathogenesis of STEC infection. The mean time from production of levels of Shiga toxin 2e
(Stx2e) detectable in the feces (day 1) to the onset of clinical disease (neurologic disturbances
or death) was 5 days (range, 3–9). Bacterial colonization and titers of Stx2e in the ileum
peaked at 4 days after inoculation in pigs without signs of clinical disease and at 6 days after
inoculation in clinically affected pigs. Animals with the greatest risk of progressing to clinical
disease tended to have the highest fecal toxin titers ( >1 : 4096). Stx2e was detected in the red
cell fraction from blood of some pigs showing clinical signs of edema disease but was not
detected in the serum or cerebrospinal fluid.
Shiga toxin–producing Escherichia coli (STEC) cause diar-
rhea, hemorrhagic colitis, and hemolytic-uremic syndrome
(HUS) in humans. These strains of E. coli are often referred
to as enterohemorrhagic E. coli (EHEC) because of their pro-
pensity to cause hemorrhage in the human intestinal tract. In-
fection is usually transmitted by the consumption of contam-
inated food or water or, secondarily, by person-to-person
contact [1]. STEC produce several distinct Shiga toxins: Stx1,
which is nearly identical to the toxin produced by Shigella dy-
senteriae, and Stx2 and its variants, Stx2c, Stx2d, and Stx2e.
EHEC strains produce some combination of Stx1, Stx2, and/
or Stx2c or Stx2d [2]. Strains of E. coli that cause edema disease
of swine produce Stx2e [3, 4]. Shiga toxins are composed of an
enzymatically active A subunit surrounded by a pentamer of
B subunits that recognize specific glycolipid receptors [5, 6].
The A subunit enters the host cell and mediates cell death by
the inhibition of protein synthesis at the ribosomal level [7].
Shiga toxins induce vascular damage [8–10], which can lead to
the systemic complications of STEC infection: acute renal fail-
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ure, hemolytic anemia, and thrombocytopenia in HUS and
edema and vascular necrosis in edema disease of swine.
Different aspects of EHEC disease can be reproduced ex-
perimentally in rabbits, mice, neonatal calves, and gnotobiotic
pigs [11–15]. STEC also cause naturally occurring dysentery in
calves [16–19]. However, there is no evidence that the disease
in calves involves toxemia or systemic vascular damage [15].
Idiopathic cutaneous and renal glomerular vasculopathy of
greyhound dogs is thought to be caused by STEC infection [20,
21].
Edema disease is a naturally occurring disease of young pigs
that involves systemic vascular damage as a result of intestinal
infection with STEC that are host adapted to swine [22]. The
hallmark of clinical edema disease is neurologic impairment
and death. Gross lesions include edema of the eyelids, mes-
entery, and gastrointestinal tract [23, 24]. Necrosis of the ar-
terioles in the intestinal tract and brain is a characteristic mi-
croscopic lesion [25, 26]. Like HUS, edema disease often has
a prodromal phase of diarrhea. However, in edema disease, the
diarrhea is due to heat-stable enterotoxin (STa and/or STb) and
is only rarely associated with intestinal hemorrhage [24, 27].
Stx2e is not enterotoxigenic in pigs [28]. The E. coli strains that
cause edema disease colonize the small intestines of pigs by
fimbrial adhesion [29–32]. In contrast, EHEC strains are
thought to colonize the colons of humans [33]. Furthermore,
colonization by some EHEC is thought to be mediated, at least
in part, by an attaching and effacing mechanism similar to that
used by enteropathogenic E. coli [34–36]. However, EHEC
strains that lack the attaching and effacing gene, eae, also cause
hemorrhagic colitis and HUS in humans and presumably col-
onize by another mechanism(s) [37–39].
Although much is known about the pathogenesis of STEC
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Figure 1. Clinical disease, vascular necrosis (VN), and geometric mean fecal Shiga toxin 2e titer (log10) of pigs after inoculation with Shiga
toxin–producing Escherichia coli strain S1191. Clinical, pigs ( ) that developed clinical edema disease; asymptomatic, pigs ( ) that didn = 16 n = 34
not develop clinical edema disease.
infections, the temporal and quantitative relationships between
intestinal colonization, toxin production, toxemia, and the clin-
ical manifestations of toxemia due to Shiga toxin have not been
adequately defined. In this study, we used edema disease to
define stages in the pathogenesis of STEC disease. We deter-
mined the times from inoculation to the peak of intestinal col-
onization with STEC and to the peak of Stx2e titers in the
intestinal content and feces. We also sought to determine
whether Stx2e titers in the feces and blood were predictive of
systemic disease and the temporal and quantitative relation-
ships between toxin production and systemic disease.
Materials and Methods
Bacterial strains. E. coli S1191 (serogroup O139) was first iso-
lated from a clinical case of edema disease [3]. This strain is he-
molytic on sheep blood agar (SBA) and produces Stx2e, heat-stable
enterotoxin STb, and F18 fimbriae, which mediate attachment to
the porcine small intestine [29–32]. S1191 is resistant to chloram-
phenicol. E. coli 123 (serogroup O43) was isolated from a healthy
pig and is not pathogenic. Inocula were prepared as described else-
where [40].
Experimental design. Three-week-old pigs (weaned at 14 days
of age, all from the same commercial herd) were randomly assigned
to groups of controls or principals. Pigs were acclimated to the diet
of 21% protein for 4 days before challenge [41]. Rooms were kept
at 217C, and heat lamps were available. Pigs were weighed at 21,
7, and 14 days after inoculation. Rectal swabs were collected before
inoculation and at days 2 and 4 after inoculation. The principals
(a total of 50 from 3 replicates of the experiment) were orally
inoculated with 1010 cfu of strain S1191 in a gelatin capsule, and
controls ( ) were inoculated with 1010 cfu of strain 123.n = 34
Individual fecal samples were collected daily from all principals
and 3 controls on days 1–10 after inoculation and assayed for free
fecal Stx2e. Pigs were observed at least twice daily for signs of
clinical edema disease and were killed and necropsied when ad-
vanced neurologic signs were detected. Randomly selected principal
pigs without signs of clinical edema disease were killed and nec-
ropsied on days 2, 4, 6, 8, 10, 12, and 14 after inoculation (3/day
on days 2–10 and 2/day on days 12–14). Randomly selected control
pigs were killed and necropsied on days 1, 5, and 13 after inocu-
lation (3/day on days 1 and 5 and 8/day on day 13). Blood samples
(serum or whole blood with EDTA) were collected from some pigs
before death. At necropsy, 5-cm sections of ileum and colon were
collected for bacteriologic counts. Contents from ileum, colon, and
rectum (feces) were collected for toxin assay. Tissue samples from
ileum, brain stem, colon, and kidney were collected for histologic
examination. Attempts to collect cerebrospinal fluid from clinically
affected principals and from controls at necropsy yielded acceptable
(blood-free) samples for toxin assay from 5 principals and 2
controls.
Pigs that died were also necropsied, and (except for 1 pig) tissue
samples were collected for histologic examination. However, be-
cause of the potential for postmortem bacterial proliferation and
toxin production, samples for bacteriology and toxin assay were
not collected from pigs found dead. At the end of the experiment,
14–15 days after inoculation, the remaining principals were killed
and necropsied, and their tissues were examined histologically.
Bacteriology. Intestinal samples were immediately placed on
ice and processed within 2 h of collection. Samples for quantitative
bacteriology were diluted in 20 mL of PBS and processed in a
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Table 1. Titers of Shiga toxin 2e in feces of selected pigs after inoculation with Shiga toxin–producing Escherichia
coli S1191.
Pig Status
Vascular
necrosis
Titera at day after inoculation
1 2 3 4 5 6 7 8 9 10
727 Asymptomatic 1 NT 128 131,072 8192 65,536 131,072 131,072 32,768 8192 128
635 Asymptomatic 2 128 64 128 512 256 128 NT 512 64 64
730 Asymptomatic 1 128 512 4096 2048 16,384 NT 1024 1024 128 128
631 Clinical 2 128 2048 4096 4096b
621 Clinical 2 256 8192 16,384 1024 4096b
616 Clinical 1 64 512 2048 512 256 131,072 131,072b
NOTE. Aymptomatic, pigs that did not develop clinical edema disease; clinical, pigs that developed clinical edema disease; NT, not
tested.
a Reciprocal of toxin titer.
b Died or killed after developing signs of edema disease.
Stomacher laboratory blender (Seward Medical, London, UK) for
1 min. Samples were serially diluted 10-fold in PBS, inoculated
onto SBA containing chloramphenicol (30 mg/mL), and incubated
at 377C overnight. Pigs were tested for preexisting infection with
Stx2e1 E. coli as follows. Rectal swabs from pigs at day 21 after
inoculation were inoculated onto SBA without antibiotics. He-
molytic E. coli recovered were tested for the presence of genes
encoding Stx2, by use of a multiplex polymerase chain reaction
assay [42]. Rectal swabs from principals after challenge were in-
oculated onto SBA with chloramphenicol, to confirm that pigs were
colonized by S1191.
Assay for Stx2e. Assays for Stx2e were done on monolayers
of Vero cells as previously described [43, 44]. All samples were
stored at 47C until assayed. Pilot studies indicated that storage at
47C or at freezing did not affect Stx2e titers of fecal or intestinal
samples (unpublished data). Fecal and intestinal samples were pro-
cessed by a modification of the method of Karmali et al. [45].
Samples were centrifuged at 7600 g for 10 min, and the supernatant
was removed and centrifuged at 16,000 g for 10 min in a microfuge
and then sterilized through a 0.22-mm filter. PBS (1 vol/1 vol feces)
was added after the first centrifugation step if the sample did not
contain 2 mL of supernatant. The sample was mixed well and
recentrifuged twice. Intestinal and fecal samples were initially di-
luted 1 : 32, because preliminary studies indicated that there was
nonspecific toxicity to Vero cells at lower dilutions in normal pig
feces. Blood samples were centrifuged at 1500 g for 10 min. The
plasma and buffy coat were removed, and the whole red blood
cells were used in the assay. Preliminary in vitro studies, in which
purified Stx2e was added to whole blood, indicated that the ma-
jority of the Stx2e was detected in the red blood cell fraction (un-
published data). Twofold dilutions of red blood cells were made in
Hanks’ balanced salt solution without Ca or Mg rather than in
tissue culture medium. Blood samples were considered positive if
the titer was 11 : 8, because there was nonspecific Vero cell toxicity
at lower dilutions in the blood of a few normal pigs. Serum and
cerebrospinal fluid were also assayed for Stx2e. All positive blood
samples and at least 1 positive intestinal sample from each pig were
neutralized with bovine polyclonal antibody that neutralizes Stx2
and Stx2e [46]. The intestinal samples were diluted to titers of
∼1 : 100 before neutralization. Fetal calf serum was used as an
antibody-negative neutralization control. Samples were considered
neutralized and their Vero toxic activity to be due to Stx2e if the
polyclonal antibody reduced the toxin titer by >4-fold [47].
Histopathology. Samples were fixed in 10% formalin, processed
by standard procedures, and stained with hematoxylin-eosin [25].
The slides were numerically coded and examined with a light mi-
croscope by 2 investigators who were not aware of the challenge
strain or toxin levels for the pigs under examination.
Statistics. The weight gain of principal and control pigs was
compared by use of a one-way analysis of variance. Pigs that died
or were killed before day 7 were not included in the weight analysis.
Average toxin titers were calculated as the geometric means of the
reciprocal value. Differences in intestinal toxin titers among dif-
ferent tissue sites were compared by one-way analysis of variance
(mixed model). Fecal toxin titers were analyzed with repeated-mea-
sures analysis of variance for days 1–5 after inoculation. Statistical
analysis was not done on fecal toxin titers from days 6–10 after
inoculation because of the small number of clinical pigs still sur-
viving. Average colony-forming units of bacteria were calculated
as the geometric means.
Results
Clinical signs. Nine of the 50 principal pigs exhibited ataxia
and circling or became moribund and were killed. An additional
7 principal pigs did not exhibit neurologic signs during obser-
vation but were found dead. Edema disease (characterized by
the presence of gross edema, fibrinous exudates, or microscopic
vascular lesions) was determined to be the cause of neurologic
signs or death in all 16 of these animals. Clinical edema disease
(signs or death) occurred 4–10 days (mean, 6) after inoculation
(figure 1). None of the control pigs exhibited signs of edema
disease or died. Mild diarrhea of unknown cause occurred in
some principal and control pigs before inoculation and spo-
radically in a few controls after challenge. Diarrhea occurred
consistently in the principal pigs on days 2–8 after inoculation.
The mean weight (5SD) of principals with clinical disease that
survived to 7 days after inoculation tended to be less (5.3 5
kg) than that of asymptomatic principals (no neurologic0.3
signs or edema; kg) and controls ( kg). The6.2 5 1.1 6.3 5 1.0
mean weights of asymptomatic principals and controls were
not significantly different at 7 or 14 days after inoculation.
Microscopic vascular lesions. Vascular lesions were detected
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Figure 2. Geometric mean Stx2e titers (log10) in feces of pigs inoculated with Shiga toxin–producing Escherichia coli strain S1191. Clinical,
pigs ( ) that developed clinical edema disease; asymptomatic, pigs ( ) that did not develop clinical edema disease. Bars indicate SEs.n = 16 n = 34
Slope of mean fecal toxin titer for clinical pigs 1–5 days after inoculation was greater then that for asymptomatic pigs ( ). Data wereP ! .05
analyzed by repeated-measures analysis of variance for days 1–5 after inoculation. Data from days 6–10 were not analyzed for statistical significance,
because too few pigs remained in the clinical group.
in 8 of the 15 principals with clinical disease that were examined
and in 12 of 34 asymptomatic principals. The lesions were de-
tected in the brain, ileum, and colon but not in the kidney. The
earliest detection of vascular necrosis was in clinical pigs at 5
days after inoculation and in randomly selected asymptomatic
principals at 12 days after inoculation (figure 1). None of 14
control pigs necropsied had vascular lesions.
Fecal toxin titers. Stx2e was not detected in the feces of
control pigs. Stx2e was detected in the feces of all principals
on day 1 after inoculation. Thus, the mean time from produc-
tion of Stx2e in intestine to the onset of clinical edema disease
was 5 days (range, 3–9; figure 1). The range of fecal toxin titers
varied widely both in pigs that developed and in those that did
not develop clinical signs (table 1). For example, pig 727 at-
tained fecal toxin titers of 1 : 131,072 for several days but did
not exhibit any clinical signs of edema disease. In contrast, the
peak fecal toxin titer of pig 631 was 1 : 4096 on day 3 after
inoculation, and the pig was found dead from edema disease
the following day (table 1). None of the 16 principals that
attained maximal fecal toxin titers !1 : 4096 progressed to clin-
ical disease. However, of 34 animals that attained fecal toxin
titers >1 : 4096, 16 (47%) progressed to clinical disease and 18
did not. The slope of the mean fecal toxin titer for principals
with clinical disease was significantly greater than that for
asymptomatic principals on days 1–5 after inoculation (P !
; figure 2). The mean fecal toxin titer of asymptomatic prin-.05
cipal pigs that developed vascular necrosis was not significantly
higher than that of the asymptomatic pigs without lesions.
Bacterial colonization and toxin titers in the intestine.
Stx2e1 E. coli were not detected in any of the pigs before in-
oculation. All the principals shed the inoculum strain in their
feces 2–4 days after inoculation. Control pigs did not have
detectable levels of Stx2e1 E. coli in their intestinal tracts after
inoculation. In randomly selected asymptomatic principals, the
peak of both bacterial colonization and titer of Stx2e in the
ileum occurred at 4 days after inoculation and fell sharply there-
after (figure 3). On this day, the geometric mean bacterial count
of strain S1191 in the ileum was cfu/cm, and the81.6 3 10
geometric mean toxin titer was 1 : 16,384. In the 9 pigs that
were killed with clinical signs of edema disease, the greatest
intensity of bacterial colonization and highest titer of Stx2e
occurred at 6 days after inoculation. The geometric mean den-
sity of bacteria in these 3 pigs was cfu/cm, and the82.4 3 10
geometric mean titer of Stx2e was 1 : 32,768. The toxin titers
of the colon and rectal content from randomly selected asymp-
tomatic pigs followed a course similar to that seen in the ileum
(figure 4). During the early stage of the disease (days 2–4), the
titer of Stx2e in the ileal content was significantly higher than
that in the colon or rectal content ( ).P ! .01
Titer of Stx2e in relation to the density of colonization by
strain S1191. Although the titer of Stx2e in the ileum tended
to increase with the number of STEC, there was not an absolute
correlation between toxin titer and bacterial density (figure
5). The majority of animals (14/15) that had Stx2e titers >1 :
4096 in their intestinal contents also had densities 1106 cfu/cm
of ileum. However, the individual animals that had the highest
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Figure 3. Geometric mean colony-forming units (log10) of Shiga toxin–producing Escherichia coli strain S1191 and geometric mean Shiga toxin
2e titers (log10) in ilea of randomly selected asymptomatic pigs (3 pigs/day on days 2–10 and 2 pigs/day on days 12–14).
titers of Stx2e did not have the greatest density of bacterial
colonization. A high ileal toxin titer (>1 : 8192) and a high
density of bacterial colonization (>106 cfu/cm) of the ileum
occurred in most (8/9) of the clinically affected animals ex-
amined. The only clinical pig that had a relatively low ileal
toxin titer and bacterial density at the time of necropsy (figure
5) attained a peak fecal toxin titer of 1 : 8192 at 4 days before
necropsy.
Bacterial layers, characterized by aggregates of basophilic
rod-shaped bacteria in immediate apposition to the epithelial
brush border, were detected in the ileal sections of 8 of 34
asymptomatic principals and 6 of 15 clinical pigs. The mean
bacterial count of strain S1191 in the ileum of these pigs with
bacterial layers was cfu/cm (range, !500 to ).6 102.3 3 10 1 3 10
The bacterial layers were detected as early as 2 days and as
late as 12 days (mean, 6) after inoculation in asymptomatic
principals and 5–7 days (mean, 6) after inoculation in clinical
pigs. Six of the 8 asymptomatic principals with adherent bac-
terial layers attained peak fecal toxin titers >1 : 8192. One of
those 6 attained fecal toxin titers 1 : 131,072 on day 3 and
remained clinically normal (pig 727; table 1). The mean bac-
terial count of strain S1191 in the ilea of pigs without adherent
layers was cfu/cm (range, !50 to ). Bacterial5 82.9 3 10 7.7 3 10
layers were not detected in sections of colon. None of the 14
control pigs necropsied had detectable adherent bacteria in their
intestinal sections.
Stx2e in blood and cerebrospinal fluid. Blood samples were
obtained from 25 principal pigs, 7 of which were exhibiting
clinical signs of edema disease at the time the blood was col-
lected (before death). Stx2e was detected in the red cell fraction
of blood from 5 of 7 animals with clinical edema disease (table
2). The mean titer of Stx2e in the blood of these 5 animals was
1 : 64 (range, 1 : 16–1 : 512). The ileal and peak fecal toxin titers
of these 5 animals ranged from 1 : 8192 to 1 : 65,536 and from
1 : 16,384 to 1 : 131,072, respectively. The ileal and peak fecal
toxin titers of the 2 clinical pigs that did not have detectable
Stx2e in blood ranged from 1 : 64 to 1 : 32,768 and from
1 : 8192 to 1 : 16,384, respectively. The blood from the 18
asymptomatic pigs and 8 controls examined did not have de-
tectable toxin. The cerebrospinal fluid samples from the 5 clin-
ical and 2 control pigs examined were also negative. All the
serum samples from the 7 clinical, 18 asymptomatic principal,
and 8 control pigs examined were negative for Stx2e. Serum
from 1 control animal was toxic to Vero cells, but that activity
was not neutralized by bovine antibody to Stx2.
Serum samples collected at the end of the experiment were
also assayed for Stx2e-neutralizing antibodies [44]. The geo-
metric mean neutralizing titers for control pigs and asympto-
matic principal pigs were 1 : 4 and 1 : 5, respectively.
In an experiment similar to that reported here but conducted
as part of a different study, we detected Stx2e in the red cell
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Figure 4. Geometric mean titers of Shiga toxin 2e (log10) from ileal, colonic, and rectal contents of randomly selected asymptomatic pigs
inoculated with Shiga toxin–producing Escherichia coli strain S1191 (3 pigs/day on days 2–10 and 2 pigs/day on days 12–14). *Titers were
significantly greater in ileum than in colon or rectum on days 2 and 4 after inoculation ( ); data were analyzed by mixed-model analysisP ! .01
of variance.
Table 2. Titers of Shiga toxin 2e at time of death in ilea and blood of pigs inoculated with Shiga
toxin–producing Escherichia coli S1191.
Status
Titera in ileum Titera in blood
Range Mean No. positive/no. tested Range Mean No. positive/no. tested
Clinical 64–65,536 16,384 7/7 16–512 64 5/7
Asymptomatic 64–16,384 709 17/17 ND 0/18
Control ND 0/8 ND 0/8
NOTE. Clinical, pigs that developed clinical edema disease; asymptomatic, pigs that did not develop clinical
edema disease; ND, none detected.
a Reciprocal of toxin titer.
fraction from the blood of 5 of 8 clinical and 2 of 12 asymp-
tomatic pigs infected with strain S1191 (unpublished data).
Discussion
The reason(s) for the variable latent period of several days
between the production of Stx2e in the intestine and the onset
of systemic disease manifested as clinical signs or vascular ne-
crosis (figure 1) is not known. Because the delay between in-
travenous administration of purified Stx2e and the onset of
systemic disease in pigs is only 7–28 h [22], it seems likely that
much of the latent period reflects the time required to attain
critical levels of toxin in blood and/or vascular endothelium.
Presumably, the time required to attain critical systemic levels
of toxin is a function of the amount produced and the rate of
transport across intestinal epithelium into blood [48, 49]. The
onset of vascular necrosis in asymptomatic principals at 12 days
after inoculation, well after the peak of toxin production (fig-
ures 1 and 3), leads us to speculate that Stx2e may act accu-
mulatively during STEC infections. Whatever the mechanism(s)
involved in the delay between the onset of toxin production
and clinical disease, the occurrence of the delay suggests use of
the edema disease model to determine if systemic disease can
be prevented by intervention with antibody [50] or other anti–
Shiga toxin therapy during the latent period.
The data indicate that fecal toxin titers were reflective of
intestinal toxin titers (figure 4). Fecal toxin titers of clinical pigs
as a group were significantly greater than those of asympto-
matic principals (figure 2). Furthermore, none of the pigs that
attained fecal toxin titers !1 : 4096 progressed to clinical dis-
ease, but nearly 50% of those that did attain titers >1 : 4096
developed clinical disease. However, the range of toxin titers
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Figure 5. Titer of Shiga toxin 2e (log10) relative to density of bacterial colonization (log10) in ilea and occurrence of clinical edema disease in
pigs inoculated with Shiga toxin–producing Escherichia coli strain S1191.
in individual pigs varied widely both in clinical and in asymp-
tomatic principals (figure 2, table 1). Thus, fecal toxin titers
tended to correlate with the relative risk of clinical disease for
a group of pigs but (because of variable susceptibility of in-
dividual pigs to intestinal toxin) were not predictive for indi-
vidual pigs. These data are consistent with the notion that the
risk of clinical disease during human STEC infections increases
with the level of intestinal toxin [51] but that intestinal toxin
levels are not predictive of clinical outcome for individual pa-
tients [45, 52].
In general, the density of STEC colonization in the intestine
was reflected by the titer of Stx2e in the gut contents. However,
the individual animals with the highest titers of Stx2e did not
have the greatest density of STEC colonization. One possible
explanation for these results is that toxin production by strain
S1191 is inducible in vivo and is stimulated by attachment to
the intestinal wall or by interaction with metabolites in the
intestinal lumens of some animals. We do not have any addi-
tional evidence for this hypothesis. In vitro–grown cultures of
S1191 routinely produce an Stx2e titer of 1 : 1000 in culture
supernatant, but sonic lysates of these same cultures have titers
that are 100-fold higher [3]. Some of the pigs in this study had
intestinal Stx2e titers similar to the titers of sonic lysates of
S1191. Some EHEC strains produce a variant of Stx2 (Stx2d)
that is activated by mouse or human intestinal mucus [53]. In
the presence of this activator, toxin titers are increased 100-fold
per cfu of bacteria. Stx2e produced by strain S1191 was not
activated in vitro by mouse or human mucus, but porcine mu-
cus was not tested [53]. However, the cytotoxicity of purified
Stx2e [28] and the culture supernatant of strain S1191 (unpub-
lished data) was not altered by incubation with intestinal fluid
from pigs. The fact that Stx2e titers were higher in ileum than
in colon or rectum suggests that small intestine may be the
major site of Shiga toxin production in this model of STEC
infection. The small intestine is the site of adhesion to intestinal
epithelium (mediated by F18 fimbriae) during colonization by
edema disease–causing strains of STEC [23, 27, 29–32]. We
speculate further that STEC adherent to intestinal epithelium
may be in a niche that enhances production, release, or acti-
vation of Shiga toxin. In contrast to the fimbria-mediated ileal
colonization by STEC in edema disease, many (but not all)
EHEC apparently colonize human colon, at least in part, via
the attaching/effacing mechanism. Such differences in site and
attachment mechanism among bacterial species may cause spe-
cies differences in production, release, activation, or absorption
of Shiga toxin. Therefore, results from edema disease may not
be directly applicable to hemorrhagic colitis and HUS.
Early fecal samples greatly increase the recovery of E. coli
O157:H7, a serotype of STEC frequently associated with hu-
man EHEC infections [54–57]. The data from the study re-
ported here also emphasize the importance of fecal samples
collected early in the disease. By 6 days after inoculation, the
density of STEC in the ilea of randomly selected asymptomatic
pigs had dropped to 104 cfu/cm, and toxin titers in the intestinal
content were !1 : 500 (figure 3). Even in pigs with clinical signs,
the mean bacterial count in the ileum dropped by 2 orders of
magnitude, and the mean toxin titer dropped from 1 : 32,768
to 1 : 9506 between days 6 and 7. The delay in obtaining fecal
samples may be one explanation for the comparatively low fecal
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toxin titers reported from patients with EHEC infections [45,
52].
Some asymptomatic pigs had fecal toxin titers 110-fold
higher (1 : 131,072) than the apparent minimum threshold level
(1 : 4096) required for clinical disease (table 1). It may be that
not all pigs transport an equal percentage of free toxin from
the intestine into the blood. Previous studies indicate that pu-
rified Stx2e given intraintestinally does not cause clinical edema
disease. However, when sodium deoxycholate is given to in-
crease intestinal permeability, intraintestinal Stx2e causes clin-
ical edema disease [49]. Alternatively, differences in the avail-
ability of receptors on erythrocytes and/or blood vessels may
explain the variability among pigs in response to intestinal toxin
loads [5]. We cannot exclude the possibility that variation in
preexisting Stx2e antibody levels contributed to the variable
susceptibility of pigs to clinical disease. However, we think that
this is unlikely, because, in our experience [25, 41, 44], weanling
pigs do not have detectable levels of serum Stx2e antitoxin
before vaccination or challenge with STEC. Furthermore, as-
says of serum from the pigs used in the work reported here
indicate little or no preexisting Stx2e antitoxin. Adherent layers
of bacteria were demonstrated in the ilea of some but not all
principals. It seems unlikely that this contributed to the variable
susceptibility of pigs to toxin, for several reasons: first, adherent
bacteria probably occurred segmentally and at varying times
during the disease [23]. Adherent layers of STEC probably oc-
curred at some site and time in most principals; otherwise, the
STEC could not have colonized intensively enough to attain
high toxin titers. Next, 6 of the 8 asymptomatic principals in
which adherent layers of bacteria were found attained fecal
toxin titers >1 : 8192, and 1 of those 6 attained a fecal toxin
titer of 1 : 131,072 on 3 separate days. Finally, in a pilot ex-
periment, we found that all 4 asymptomatic principals tested
17 days after inoculation with strain S1191 had ileal epithelial
cell brush borders receptive to adhesion by F181 E. coli in vitro
(unpublished data).
To our knowledge, this is the first report of Stx2e being de-
tected in the red cell fraction of blood from individual STEC-
infected animals. This provides further evidence that Stx2e con-
tributes to the systemic damage seen in clinical edema disease
[22]. It also supports the concept that Stx2e is transported from
the gut, by the blood, to the site of tissue damage [5, 22, 49].
Previous work has demonstrated that Stx2e binds to pig eryth-
rocytes and that the tissue distribution of intravenously ad-
ministered toxin is dependent on the blood flow to particular
sites [5, 58]. The fact that we detected Stx2e in the red blood
cell fraction but not in the serum is consistent with the evidence
that Stx2e binds to erythrocytes. Presumably, the Stx2e detected
was a portion of that in equilibrium with the receptors on
erythrocytes. In contrast to our results with edema disease,
cytotoxic activity (presumed to be Shiga toxin) was detected in
the serum of gnotobiotic pigs infected with EHEC strains [59,
60]. Concentrated serum samples from mice infected with
EHEC also contained detectable Shiga toxin [61]. Our inability
to detect Stx2e in the blood of most asymptomatic infected pigs
that had high titers of Stx2e in their intestines may indicate
that the toxin had not yet entered into the blood of these an-
imals. Alternatively, erythrocyte receptors in most asympto-
matic infected pigs may not have been sufficiently saturated to
release detectable levels of toxin. In vitro studies with fluores-
cent-labeled Shiga toxin demonstrate that human erythrocytes
also bind Shiga toxin, although the degree of binding varies
considerably among donors of different blood group antigen
types [62]. This suggests that variations in the toxin binding
capacity of erythrocytes may cause variations in clinical out-
come in edema disease, as has been suggested by some but not
all studies of human STEC infections [62–66].
In conclusion, this study demonstrated a delay of several
days from the production of Stx2e to the onset of clinical dis-
ease. It also demonstrated that fecal toxin titers could be used
to identify a population of pigs that were at greatest risk for
developing clinical disease after STEC infection. However, such
titers were not predictive for individual animals. Stx2e was de-
tected in the peripheral blood of pigs with clinical disease. This
provides further evidence that Stx2e is transported, by blood,
from the gut to sites of systemic tissue damage.
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Note added in proof. Subsequent review of the histologic slides revealed vascular lesions in an additional asymptomatic
principal at 8 days postinoculation.
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